← All trials
NCT06238635
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 11, 2024
- Primary completion
- Feb 1, 2026
- Completion date
- Jul 15, 2027
- First posted
- Feb 2, 2024
- Last posted
- Jul 26, 2024
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversitySponsor investigator
- GlaxoSmithKlineCollaborator
- Harvard UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.